UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

[X] Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
   
  For the quarterly period ended March 31, 2019
   
[  ] Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934
   
  For the transition period from __________  to __________
   
  Commission File Number: 333-156091

 

Alterola Biotech, Inc.

(Exact name of Registrant as specified in its charter)

 

Nevada TBA
(State or other jurisdiction of incorporation or organization)  (IRS Employer Identification No.)

 

340 S Lemon Ave # 4041

Walnut, California 91789

(Address of principal executive offices)

 

512-821-2121
(Registrant’s telephone number)
 
 _______________________________________________________________
(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days

[ ] Yes [X] No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [X] Yes [ ] No

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.

 

[  ] Large accelerated filer [  ] Accelerated filer
[X] Non-accelerated filer [X] Smaller reporting company
  [  ] Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

[X] Yes [ ] No

 

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 330,980,000 shares as of December 22, 2020.

 

   


 

 

TABLE OF CONTENTS

 

Page

 

PART I – FINANCIAL INFORMATION

 

Item 1: Financial Statements 3
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations 4
Item 3: Quantitative and Qualitative Disclosures About Market Risk 6
Item 4: Controls and Procedures 6

 

PART II – OTHER INFORMATION

 

Item 1: Legal Proceedings 7
Item 1A: Risk Factors 7
Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 7
Item 3: Defaults Upon Senior Securities 7
Item 4: Mine Safety Disclosure 7
Item 5: Other Information 7
Item 6: Exhibits 7

 

  2  

PART I - FINANCIAL INFORMATION

 

Item 1.     Financial Statements

 

Our financial statements included in this Form 10-Q are as follows:

 

F-1   Balance Sheets as of March 31, 2019 and September 30, 2018 (unaudited);

 

F-2  

Statements of Operations for the three and six months ended March 31, 2019 and 2018 (unaudited);

 

F-3 Statement of Stockholders’ Deficit for the period ended March 31, 2019

 

F-4   Statements of Cash Flow for the six months ended March 31, 2019 and 2018 (unaudited);

 

F-5   Notes to Financial Statements.

 

These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the Securities Exchange Commission (“SEC”) instructions to Form 10-Q.  In the opinion of management, all adjustments considered necessary for a fair presentation have been included.  Operating results for the interim period ended March 31, 2019 are not necessarily indicative of the results that can be expected for the full year.

 

  3  

 

ALTEROLA BIOTECH, INC.

BALANCE SHEETS

AS OF MARCH 31, 2019 AND SEPTEMBER 30, 2018

 

    March 31, 2019
(unaudited)
  September 30, 2018
ASSETS              
Current Assets              
Funds held in attorney trust   $ 14,742     $ 14,742
Deferred stock compensation     —         36,000
Total current assets     14,742       50,742
               
               
TOTAL ASSETS   $ 14,742     $ 50,742
               
LIABILITIES AND STOCKHOLDERS’ DEFICIT              
               
Current Liabilities              
Accounts payable   $ 18,500     $ 24,249
Accrued interest     0       1,360
Accrued directors fees     120,000       60,000
Advances from related party     2,250       750
Current portion of notes payable     0       0
Total Current Liabilities     140,750       86,359
               
Non current portion of notes payable     0       19,950
Total Liabilities     140,750       106,309
               
Stockholders’ Deficit              
Preferred Stock, $.001 par value, 10,000,000 shares authorized, -0- shares issued and outstanding     —         —  
Common Stock, $.001 par value, 140,000,000 shares authorized, 115,980,000 shares issued and outstanding     115,980       115,980
Additional paid-in capital     562,587       541,028
Deficit accumulated     (804,575 )     (712,575)
Total Stockholders’ Deficit     (126,008 )     (55,567)
               
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT   $ 14,742     $ 50,742

 

See accompanying notes to financial statements.

 

  F- 1  

 

ALTEROLA BIOTECH, INC.

STATEMENTS OF OPERATIONS (unaudited)

FOR THE THREE MONTHS AND SIX MONTHS ENDED MARCH 31, 2019 AND 2018

 

    Three months ended   Six months ended
    March 31, 2019   March 31, 2018   March 31, 2019   March 31, 2018
                 
REVENUES   $ 0     $ 0     $ 0     $ 0
                               
OPERATING EXPENSES                              
     Stock based compensation     9,000       0       36,000       0
Accounting and audit fees     250       250       500       500
Legal fees     0       1,000       (5,208 )     2,000
Directors fees     30,000       0       60,000       0
General and administrative expenses     114       5       459       5
TOTAL OPERATING EXPENSES     39,364       1,255       91,751       2,505
                               
LOSS FROM OPERATIONS     (39,364 )     (1,255 )     (91,751 )     (2,505)
                               
OTHER INCOME (EXPENSE)                              
Interest expense     (0 )     (4,625 )     (249 )     (9,250)
TOTAL OTHER INCOME (EXPENSE)     (0 )     (4,625 )     (249 )     (9,250)
                               
PROVISION FOR INCOME TAXES     0       0       0       0
                               
NET INCOME (LOSS)   $ (39,364 )   $ (5,880 )   $ (92,000 )   $ (11,755)
                               
NET INCOME (LOSS) PER SHARE: BASIC AND DILUTED   $ (0.00 )   $ (0.00 )   $ (0.00 )   $ (0.00)
                               
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED     115,980,000       114,980,000       115,980,000       114,980,000

 

See accompanying notes to financial statements.

 

  F- 2  

 

ALTEROLA BIOTECH, INC.

STATEMENT OF STOCKHOLDERS’ DEFICIT (unaudited)

FOR THE PERIOD ENDED DECEMBER 31, 2018

 

      Common stock                        
      Shares       Amount       Additional paid-in capital       Accumulated Deficit       Total
Balance, September 30, 2017
    114,980,000       114,980       169,850       (579,508 )     (294,678)
Common stock issued for services     1,000,000       1,000       89,000               90,000
Capital contribution from forgiveness of debt                     282,178               282,178
Net income (loss) for the period ended September 30, 2018                             (133,067 )     (133,067)
Balance, September 30, 2018     115,980,000     $ 115,980     $ 541,028     $ (712,575 )   $ (55,567)
Capital contribution from forgiveness of debt                     21,559               21,559
Net income (loss) for the period ended March 31, 2019                             (92,000 )     (92,000)
Balance, March 31, 2019     115,980,000     $ 115,980     $ 562,587     $ (804,575 )   $ (126,008)

 

See accompanying notes to financial statements.

 

  F- 3  

 

ALTEROLA BIOTECH, INC.

STATEMENTS OF CASH FLOWS (unaudited)

FOR THE SIX MONTHS ENDED MARCH 31, 2019 AND 2018

 

    Six months ended
    March 31, 2019   March 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES              
Net income (loss) for the period   $ (92,000 )   $ (11,755)
Adjustments to reconcile net loss to net cash used in operating activities:              
Stock based compensation     36,000       0
Changes in assets and liabilities:              
Increase (decrease) in accounts payable     54,251       2,505
Increase (decrease) in accrued interest     249       9,250
Increase (decrease) in advance from related party     1,500       0
Net Cash Used by Operating Activities     0       0
               
CASH FLOWS FROM INVESTING ACTIVITIES              
Acquisition of intellectual property     0       0
Website development     0       0
Net Cash Used by Investing Activities     0       0
               
CASH FLOWS FROM FINANCING ACTIVITIES              
Proceeds from notes payable     0       0
Net Cash Provided by Financing Activities     0       0
               
Net Increase (Decrease) in Cash and Cash Equivalents     0       0
               
Cash and cash equivalents, beginning of period     0       0
Cash and cash equivalents, end of period   $ 0     $ 0
               
SUPPLEMENTAL CASH FLOW INFORMATION              
Interest paid   $ 0     $ 0
Income taxes paid   $ 0     $ 0
               
NON-CASH INVESTING AND FINANCING INFORMATION              
Deferred financing costs related to notes payable   $ 0     $ 0

 

See accompanying notes to financial statements.

 

  F- 4  

 

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2019

 

NOTE 1 – NATURE OF BUSINESS

 

Alterola Biotech, Inc. (“Alterola” and the “Company”) is a development stage company and was incorporated in Nevada on July 21, 2008. The Company was formed to acquire exploration and development stage mineral properties.

 

On October 1, 2008, the Company incorporated JRE Exploration Ltd, (“JRE”) a wholly owned subsidiary in Canada to hold its Canadian mineral claims.

 

On May 3, 2010, the Company changed its focus to the development of intellectual property and accordingly sold JRE to the former president. In keeping with the change of business focus, on July 9, 2010, the Company changed its name to Alterola Biotech Inc.

 

In April 2017, the Company entered into an assignment agreement with its director to convey all assets and intellectual property to its former director for the cancellation of 37,000,000 shares of the Company.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Accounting Basis

The Company uses the accrual basis of accounting and accounting principles generally accepted in the United States of America (“GAAP” accounting).  The Company has a September 30 fiscal year end.

 

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and Equivalents

For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.

 

  F- 5  

  

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2019

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Funds held in attorney trust account

The company does not have its own bank account. Funds held in attorney trust account represent funds held on behalf of the Company in trust by its legal counsel.

 

Fair Value of Financial Instruments

Alterola’s financial instruments consist of cash and equivalents, accrued expenses, accrued interest and notes payable. The carrying amount of these financial instruments approximates fair value (“FV”) due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements.

 

FV is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The FV should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the FV of liabilities should include consideration of non-performance risk including our own credit risk.

 

In addition to defining FV, the disclosure requirements around FV establish a FV hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring FV are observable in the market. Each FV measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the FV measurement in its entirety. These levels are:

 

Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

 

Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

  F- 6  

  

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUIDTED FINANCIAL STATEMENTS

MARCH 31, 2019

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

 

Fair Value of Financial Instruments (continued)

Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The FV are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

 

The carrying value of the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable are valued using level 1 inputs. The Company believes that the recorded values approximate their FV due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.

 

Income Taxes

Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized.

 

Revenue Recognition

On January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 605. As of and for the year ended September 30, 2018, the financial statements were not materially impacted as a result of the application of Topic 606 compared to Topic 605.

 

Loss Per Common Share

Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.

 

Stock-Based Compensation

Stock-based compensation is accounted for at FV in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options

 

During the year ended September 30, 2018, the Company issued 1,000,000 shares of common stock to an officer for services rendered with a deemed value of services provided of $90,000 for services rendered from April 1, 2018 to January 31, 2019. As of September 30, 2018, $36,000 of stock-based compensation has been recorded as a prepaid expense. As of March 31, 2019, the stock based compensation has been fully amortized.

 

Recent Accounting Pronouncements

Alterola does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

 

  F- 7  

  

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2019

 

NOTE 3 – ACCOUNTS PAYABLE

 

Accounts payable consisted of the following at March 31, 2019 and September 30, 2018:

 

    March 31, 2019   September 30, 2018
Audit fees   $ 0     $ 1,000
Accounting     5,100       4,350
Legal fees and transfer agent     13,400       18,899
Total Accounts payable   $ 18,500     $ 24,249

 

NOTE 4 – NOTES PAYABLE

 

Notes payable consisted of the following at March 31, 2019 and September 30, 2018:

 

    March 31, 2019   September 30, 2018
               
Note payable, secured by assets of the company, bearing interest at 5% due on April 25, 2023     0       19,950
      0       19,950
Less: current portion     (0 )     (0)
               
Total Notes payable   $ 0     $ 19,950

  

  F- 8  

 

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2019

 

NOTE 4 – NOTES PAYABLE (CONTINUED)

 

The Convertible note was convertible at the option of the holder. The number of shares of common stock into which the convertible note was to be converted is determined by the Fair Market Price (“FMV”) of the common stock at the date of conversion. In the event there is no determinable market price the FMV shall be:

 

a) The share price at the last private offering of the common stock, or, b) the 30 day moving average of the Common Stock in the event a public listing of the common stock has taken place.

 

Interest expense was $249 and $9,250 for the periods ended March 31, 2019 and 2018, respectively.

 

On March 28, 2018 the Company entered into agreements with its debt holders to forgive promissory notes and accrued interest of $ 282,178. As a result, the Company has reclassified debt and interest payable to additional paid in equity for $ 282,178 in the financial statements for the year ended September 30, 2018. On December 31, 2018 the Company entered into agreements with a debt holder to forgive additional promissory notes and accrued interest of $21,559. As a result, the Company has reclassified debt and interest payable to additional paid in equity for $21,559 in the financial statements for the period ended December 31, 2018.

 

NOTE 5 – CAPITAL STOCK

 

The Company has 140,000,000 shares of $0.001 par value common stock authorized and 10,000,000 shares of $0.001 par value preferred stock authorized.

 

On April 10, 2017, a former director of the Company surrendered for voluntary cancellation, 37,000,000 shares of common stock with a deemed value of $ 37,000.

 

On April 10,2017, the Company issued 37,000,000 shares of common stock to its director for services with a deemed value of $ 37,000.

 

On June 28, 2018 the company issued one million common shares for consulting services with a deemed value of $90,000..

 

The Company has 115,980,000 and 115,980,000 shares of common stock issued and outstanding as of March 31, 2019 and September 30, 2018 respectively. There are no shares of preferred stock issued and outstanding.

 

NOTE 6- INCOME TAX

 

Due to uncertainties surrounding the Company’s ability to generate future taxable income to realize these assets, a full valuation allowance has been established to offset the net deferred tax asset. The income tax effects of the Tax Cuts and Jobs Act have been completed in accordance with FASB ASC 740.

 

  F- 9  

 

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2019

 

NOTE 6 – INCOME TAXES (continued)

 

The provision for income tax consists of the following components at March 31, 2019 and 2018:

 

    2019   2018
Current:              
Federal income taxes (benefit)     (31,280 )   $ (3,997)
State income taxes     —         —  
Deferred Benefit from net operating loss     —         —  
    $ (31,280 )   $ (3,997)

 

The following reconciles income taxes reported in the financial statements to taxes that would be obtained by applying regular tax rates to income before taxes:

 

    2019   2018
Expected tax expense (benefit) using regular rates   $ 31,280     $ 3,997
State minimum tax              
Valuation allowance     (31,280 )     (3,997)
Tax Provision   $ —       $ —  

 

The Company has loss carry forwards totaling $856,821 that may be offset against future federal income taxes. If not used, the carry forwards will expire between 2028 and 2039. The change in control may limit the amount of loss carryforward that may be utilized.

 

At March 31, 2019 and September 30, 2018, the significant components of the deferred tax assets are summarized below:

 

    March  31,2019   September 30, 2018
Deferred income tax asset              
 Net operation loss carryforwards     291,319       260,039
    Total deferred income tax asset     291,319       260,039
  Less: valuation allowance     (291,319 )     (260,039)
Total deferred income tax asset   $ —       $ —  

 

The federal income tax returns of the Company for 2018 and 2017 are subject to examination by the IRS, generally for three years after they were filed.

 

NOTE 7 – RELATED PARTY TRANSACTIONS

 

Alterola neither owns nor leases any real or personal property. An officer has provided office space without charge. There is no obligation for the officer to continue this arrangement. Such costs are immaterial to the financial statements and accordingly are not reflected herein. The officers and directors are involved in other business activities and most likely will become involved in other business activities in the future.

 

During the period ended March 31, 2019, the Company accrued director’s fees payable of $120,000.

 

  F- 10  

 

ALTEROLA BIOTECH, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

MARCH 31, 2019

 

NOTE 8 – LIQUIDITY & GOING CONCERN

 

Alterola has negative working capital, has incurred losses since inception, and has not received revenues from sales of products or services. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern. As of 3/31/2019, the Company had negative working capital of $126.008 and accumulated deficit of $804,575.

 

The ability of Alterola to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

 

NOTE 9 – SUBSEQUENT EVENTS

 

In accordance with ASC Topic 855-10, the Company analyzed its operations subsequent to March 31, 2019 to the date these financial statements were issued.

 

On July 20, 2020, the Company appointed certain directors and officers. As part of the appointment, each individual received issuance of 1,000,000 shares of common stock, respectfully, valued at $10,000 per individual.

 

On September 4, 2020, the Company issued 6,000,000 shares of common stock to the newly appointed Chief Executive Officer and Director, as compensation for services to the Company, valued at $60,000.

 

On September 18, 2020, the Company issued 200,000,000 shares of common stock to Amsterdam Café Holdings Ltd, at a price of $0.001 per share, for total proceeds of $200,000.

 

On December 2, 2020, the board of directors accepted the resignations of Irving Aronson as Chairman and Director, Peter Maddocks as CFO and Director, Oliver Aubrey as Chief Medical Officer and Director, Rene Lauritsen as COO and Director, and Larson Elmore as CEO. Dr. Daniel Reshef and Lalit Kumar will remain as Directors of the Board. Mr. Elmore will continue as Vice Chairman, Director and Secretary of our company.

 


Also on December 2, 2020, we have appointed the following officers and directors: Tim Rogers as the CEO and Director, and Director, Dominic Schiller as Director & IP Counsel, Seamus McAuley as Chief Commercial Officer and Director, Daniel Reshef as Vice Chairman Medical Director and Zohar Koren as Advisory Medical Director.

 

  F- 11  

 

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.   These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions.  We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions.  Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain.  Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.  We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.

 

Overview

 

The business plan will no longer be focused on a chewing gum delivery system but will re-focus its activities to the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs and European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products .In addition, Alterola will development such bulk ingredients for supply into the cosmetic sector.

 

The IP relating to the development of chewing gum to deliver nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant is not relevant to a pharmaceutical business. These products / items will no longer be the focus of the business and will be removed from the business.

 

The new business plan of the company is for the company’s operations to be expanded and repositioned as a fully, regulatory-compliant pharmaceutical company specializing in the development of the following:

 

• cannabinoid, cannabinoid-like and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs) globally,

• pharmaceutical medicines made from cannabinoid, cannabinoid-like and non-cannabinoid APIs globally

• European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients

• European novel food approval of products containing cannabinoids, cannabinoid-like and non-cannabinoid ingredients.

• European approval of cosmetic products containing cannabinoids, cannabinoid-like and non-cannabinoid ingredients.

 

As part of its expansion strategy the company is also interested in recruiting key executives and personnel that have experience in the controlled drugs / cannabinoid medicines industry. The focus will be on recruiting outstanding talents that have contributed or can contribute more in the future with our plan of expansion.

 

The company also has interest in licensing / acquiring other IP from companies that have IP pertinent to the new pharmaceutical / food / cosmetic ingredient generation and product development strategy.

 

  4  

 

Under consideration for our acquisition strategy are companies that have existing pharmaceutical research and/or development or manufacturing capability or associated IP. Some of these companies have IP which is available to consolidate into our company strategy. These acquisition or in-licensing opportunities have various contributions to facilitate the company to develop ingredients and products for food and beverage industry in Europe.

 

The controlled drugs / cannabinoid pharmaceutical market worldwide has experienced exponential growth over the past few years in the development of products.

 

It is Alterola’s intention to develop ingredients and products on a global basis, fully compliant with the appropriate international laws and regulations and also compliant with the relevant national laws and regulations on a territory-by-territory basis.

 

Results of Operations for the Three and Six Months Ended March 31, 2019 and 2018

 

We have generated no revenues since inception and we do not anticipate earning revenues until such time that we are able to market and sell our products.

 

We incurred operating expenses of $39,364 for the three months ended March 31, 2019, compared with $1,255 for the three months ended March 31, 2018. We incurred operating expenses of $91,751 for the six months ended March 31, 2019, compared with $2,505 for the six months ended March 31, 2018.

 

Our operating expenses for the six months ended March 31, 2019 mainly consisted of $60,000 in director fees and $36,000 in stock based compensation. Our operating expenses for the six months ended March 31, 2018 consisted of $2,000 in legal fees and $500 in accounting and audit fees.

 

We recorded other expense of $0 for the three months ended March 31, 2019, as compared with $4,625 in interest expense for the three months ended March 31, 2018. We recorded other expense of $249 for the six months ended March 31, 2019, as compared with $9,250 in interest expense for the six months ended March 31, 2018.

 

We recorded a net loss of $39,364 for the three months ended March 31, 2019, compared with a net loss of $5,880 for the three months ended March 31, 2018. We recorded a net loss of $92,000 for the six months ended March 31, 2019, compared with a net loss of $11,755 for the six months ended March 31, 2018.

 

Liquidity and Capital Resources

 

As of March 31, 2019, we had $14,742 in current assets and currently liabilities of $140,750. We had a working capital deficit of $86,644 as of March 31, 2019.

 

we had no operating, investing or financing cash flows to report for the three and six months ended March 31, 2019 and 2018.

 

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next 12 months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

 

Off Balance Sheet Arrangements

 

As of March 31, 2019, we had no off balance sheet arrangements.

 

  5  

 

Going Concern

 

Our financial statements were prepared assuming we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred cumulative losses of $804,575 for the period July 21, 2008 (inception date) through March 31, 2019, expect to incur further losses in the development of our business and have been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

Item 3.     Quantitative and Qualitative Disclosures About Market Risk

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 4.     Controls and Procedures

 

Disclosure Controls and Procedures

 

We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2019. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2019, our disclosure controls and procedures were not effective due to the presence of material weaknesses in internal control over financial reporting.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis. Management has identified the following material weaknesses which have caused management to conclude that, as of March 31, 2019, our disclosure controls and procedures were not effective: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC guidelines.

 

Remediation Plan to Address the Material Weaknesses in Internal Control over Financial Reporting

 

Our company plans to take steps to enhance and improve the design of our internal controls over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the following changes during our fiscal year ending September 30, 2021: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the three months ended March 31, 2019 that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

 

  6  

 

PART II – OTHER INFORMATION

 

Item 1.     Legal Proceedings

 

We are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

 

Item 1A:  Risk Factors

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds

 

On July 20, 2020, the Company appointed certain directors and officers. As part of the appointment, each individual received issuance of 1,000,000 shares of common stock, respectfully.

 

On September 4, 2020, the Company issued 6,000,000 shares of common stock to the newly appointed Chief Executive Officer and Director, as compensation for services to the Company.

 

On September 18, 2020, the Company issued 200,000,000 shares of common stock to Amsterdam Café Holdings Ltd, at a price of $0.001 per share, for total proceeds of $200,000.

 

These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

 

Item 3.     Defaults upon Senior Securities

 

None

 

Item 4.     Mine Safety Disclosures

 

Not applicable.

 

Item 5.     Other Information

 

None

 

Item 6.      Exhibits

 

Exhibit Number Description of Exhibit
31.1 Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2 Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101** The following materials from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 formatted in Extensible Business Reporting Language (XBRL).
**Provided herewith  

 

  7  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Alterola Biotech, Inc.
   
Date: February 24, 2020
   
 

By: /s/ Tim Rogers

Tim Rogers

Title:   Chief Executive Officer and Director

 

Date: February 24, 2020
   
 

By: Larson Elmore

Larson Elmore

Title:    Interim Chief Financial Officer, Vice Chairman, Secretary and Director

 

  8  

Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Alterola Biotech (PK) Charts.
Alterola Biotech (PK) (USOTC:ABTI)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Alterola Biotech (PK) Charts.